Although activating KRAS mutations occur frequently in cancer, targeting this oncogene has proved difficult. Three groups have now identified pathways that have not been previously linked to KRAS ...

The research published August 29 in Cancer Cell, demonstrates that KRAS mutations, which occur in about 95 percent of people who have PDAC, can vary, with KRAS-G12R, KRAS-G12D, and KRAS-G12V being ...

Jazz Pharmaceuticals has agreed another pipeline-building deal, this time paying $10 million upfront for rights to a KRAS inhibitor programme from UK biotech Redx Pharma, continuing a move into ...

As China's first approved KRAS G12C inhibitor, Dupert® is Innovent's eleventh product in its commercial portfolio and is anticipated to soon benefit more lung cancer patients with the KRAS G12C ...

Distinct clinical outcomes and biological features of specific KRAS mutants in human pancreatic cancer. Cancer Cell , 2024; 42 (9): 1614 DOI: 10.1016/j.ccell.2024.08.002 Cite This Page : ...

Along with the phase 3 monotherapy trial and mid-stage extension studies in NSCLC and KRAS-mutated colorectal cancer, Novartis is also exploring use of JDQ443 in combination with other drugs.

A mutation in the KRAS gene can lead to uncontrollable cell growth and the development of cancer. Having this mutation can significantly influence the treatment and outlook of people with colon ...

The research, published August 29 in Cancer Cell, demonstrates that KRAS mutations, which occur in about 95% of people who have PDAC, can vary, with KRAS-G12R, KRAS-G12D and KRAS-G12V being the ...

A common mutation in the KRAS gene is associated with improved overall survival in pancreatic ductal adenocarcinoma (PDAC) compared with other variants, in part because the mutation appears to lead to ...